natgillin/translations-raw huggingface dataset:
Der er i kliniske undersøgelser set øget incidens af disse hændelser hos ældre og hos patienter med hjertesygdom i anamnesen. 
In clinical trials, there was an increased incidence of these events in elderly and those with a prior history of cardiac disease.
Ved 7-års opfølgning var der 93 (16,8 %) progressionshændelser i Imatinib -armen: 37 (6,7 %) omhandlede progression til accelereret fase/blastkrise, 31 (5,6 %) tab af MCyR, 15 (2,7 %) tab af CHR eller stigning i WBC, og 10 (1,8 %) dødsfald ikke relateret til CML. 
With 7 years follow-up, there were 93 (16.8%) progression events in the Imatinib arm: 37 (6.7%) involving progression to accelerated phase/blast crisis, 31 (5.6%) loss of MCyR, 15 (2.7%) loss of CHR or increase in WBC, and 10 (1.8%) CML unrelated deaths.
Du kan blive mere følsom overfor sollys, når du tager Imatinib Accord. 
You may become more sensitive to the sun while taking Imatinib Accord.
Patienter med hjertesygdom, risikofaktorer for hjerteinsufficiens eller nyreinsufficiens i anamnesen skal monitoreres omhyggeligt, og alle patienter, som har symptomer forenelige med hjerte- eller nyreinsufficiens, bør undersøges og behandles. 
Patients with cardiac disease, risk factors for cardiac failure or history of renal failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure or renal failure should be evaluated and treated.
6 doser)iii: dag 2, 3, 16, og 17 
6 doses)iii: days 2, 3, 16, and 17
Total bilirubin: >3-10 ULN ASAT: alt ULN = laboratoriets øvre normalgrænse ASAT = aspartataminotransferase 
Total bilirubin: > 3-10 ULN AST: any ULN = upper limit of normal for the institution AST = aspartate aminotransferase
Undersøgelsens primære effektvariabel var graden af det cytogenetiske hovedrespons (fuldstændigt plus partielt respons, 0-35 % Ph+-metafaser i knoglemarven). 
The primary efficacy variable of the study was the rate of major cytogenetic response (complete plus partial response, 0 to 35% Ph+ metaphases in the bone marrow).
doses)iii: dag 2 og 3 
doses)iii: days 2 and 3
Ara-C: cytosin arabinosid; CP: cyclophosphamid; DEX: dexamethason; MTX: methotrexat; 6MP: 6-mercaptopurin; VM26: teniposid; VCR: vinkristin; IDA: idarubicin; i.v. 
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6-MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v.
Kontakt din læge med det samme, hvis du oplever nogle af de følgende bivirkninger 
Tell your doctor straight away if you get any of the following
Denne fase III undersøgelse hos voksne patienter sammenlignede enkeltstof-behandling med Imatinib med behandling med en kombination af interferon-alfa (IFN) og cytarabin (Ara-C). 
This phase III study in adult patients compared treatment with either single-agent Imatinib or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C).
In vitro hæmmer Imatinib cytochrom P450 isoenzym CYP2D6-aktivitet ved koncentrationer svarende til dem, der påvirker CYP3A4-aktivitet. 
In vitro imatinib inhibits the cytochrome P450 isoenzyme CYP2D6 activity at concentrations similar to those that affect CYP3A4 activity.
Total bilirubin: >1,5-3,0 ULN ASAT: alt 
Total bilirubin: > 1.5-3.0 ULN AST: any
Den pædiatriske patient fik 400 mg/m2/daglig, hvilket efterfølgende blev øget til 520 mg/m2/daglig. 
The paediatric patient received 400 mg/m2/daily, subsequently increased to 520 mg/m2/daily.
Pakninger indeholdende 10, 30 eller 90 filmovertrukne tabletter. 
Packs containing 10, 30, or 90 film-coated tablets.
Ved brug af denne metode øgedes den estimerede kumulative responsfrekvens for førstevalgsbehandling med Imatinib fra 12 måneders behandling til 84 måneders behandling som følgende: CHR fra 96,4 % til 98,4 % og CCyR fra 69,5 % til 87,2 %). 
Using this approach, the estimated cumulative response rates for first-line treatment with Imatinib improved from 12 months of therapy to 84 months of therapy as follows: CHR from 96.4% to 98.4% and CCyR from 69.5% to 87.2%, respectively.
Kronisk myeloid leukæmi (CML). 
Chronic myeloid leukaemia (CML).
Til patienter (børn), der ikke er i stand til at synke tabletterne, kan indholdet opløses i et glas almindeligt vand eller æblejuice. 
For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of mineral water or apple juice.
Den estimerede progressionsfri overlevelse efter 84 måneder var 81,2 % i Imatinib-armen og 60,6 % i kontrolarmen (p<0,001). 
The estimated rate of progression-free survival at 84 months was 81.2% in the Imatinib arm and 60.6% in the control arm (p<0.001).
ASAT: >ULN (kan være normal eller <ULN hvis total bilirubin er >ULN) 
Total bilirubin: = 1.5 ULN AST: > ULN (can be normal or < ULN if total bilirubin is > ULN)
Sikkerhedsdatabasen for børn og unge med Ph+ ALL er meget begrænset. 
The safety database for children and adolescents with Ph+ALL is very limited though no new safety concerns have been identified.
Maksimale plasmakoncentrationer af imatinib er hos patienter 2-4 mol/l, og hæmning af CYP2D6 og/eller CYP3A4/5-medieret metabolisme af samtidigt administrerede lægemidler er derfor mulig. 
Maximal plasma concentrations of imatinib in patients are 2-4 µmol/l, consequently an inhibition of CYP2D6 and/or CYP3A4/5-mediated metabolism of co-administered drugs is possible.
• voksne patienter med inoperabel dermatofibrosarkom protuberans (DFSP) og voksne patienter med residiverende og/eller metastaserende DFSP som ikke er tilgængelig for kirurgi. 
• adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
SIKKER OG EFFEKTIV ANVENDELSE AF LÆGEMIDLET 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Årlige frekvenser af enhver type progression blev reduceret over tid med Imatinib. 
The yearly rates of progression of any type for Imatinib also decreased over time.
Imatinib blev administreret periodisk i kohorte 1-5 med stigende varighed og tidligere start med imatinib fra kohorte til kohorte; kohorte 1 fik den mindst intensive imatinibbehandling og kohorte 5 den mest intensive (længste varighed i dage med kontinuerlig, daglig imatinib-dosering i de første kemobehandlingsforløb). 
Imatinib was administered intermittently in cohorts 1-5, with increasing duration and earlier start of imatinib from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of imatinib (longest duration in days with continuous daily imatinib dosing during the first chemotherapy treatment courses).
• Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
• Do not use this medicine after the expiry date which is stated on the carton and blister after
Hvor estimeret 96 % (93 %) af patienterne med CCyR (PCyR) ved 12 måneder var fri for progression til accelereret fase/blastkrise ved 84 måneder, var kun 81 % af patienterne uden CCyR ved 12 måneder fri for progression til fremskreden CML ved 84 måneder (p<0,001 samlet, p=0,25 mellem CCyR og PCyR). 
Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to accelerated phase/blast crisis at 84 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 84 months (p<0.001 overall, p=0.25 between CCyR and PCyR).
9 Muskuloskeletale smerter under behandling med imatinib eller efter seponering er blevet observeret efter markedsføring. 
Musculoskeletal pain during treatment with imatinib or after discontinuation has been observed in post-marketing.
Pakninger indeholdende 20, 60, 120 eller 180 filmovertrukne tabletter. 
Packs containing 20, 60, 120 or 180 film-coated tablets.
I denne retrospektive analyse af total overlevelse blev Imatinibs overlegenhed vist i forhold til IFN+AraC (p<0,001); inden for 42 måneder var 47 (8,5 %) Imatinib-patienter og 63 (19,4 %) IFN+Ara-Cpatienter døde. 
In this retrospective analysis, the superiority of Imatinib over IFN+Ara-C in overall survival was demonstrated (p<0.001); within 42 months, 47 (8.5%) Imatinib patients and 63 (19.4%) IFN+Ara-C patients had died.
Bærere af HBV, hvor behandling med Imatinib Accord er nødvendig, skal overvåges tæt for tegn og symptomer på aktiv HBV-infektion i hele behandlingsperioden og i flere måneder efter behandlingsophør (se pkt. 
Carriers of HBV who require treatment with Imatinib Accord should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).
BCR-ABL-tyrosinkinasehæmmere (TKI'er) er blevet associeret med trombotisk mikroangiopati (TMA), herunder enkeltstående rapporter for imatinib (se pkt. 
BCR-ABL tyrosine kinase inhibitors (TKIs) have been associated with thrombotic microangiopathy (TMA), including individual case reports for Imatinib Accord (see section 4.8).
Imatinib Accord hæmmer væksten af disse celler i en vis undergruppe af disse sygdomme. 
Imatinib Accord inhibits the growth of these cells in a certain subtype of these diseases.
Imatinib metaboliseres primært i leveren, og kun 13% udskilles via nyrerne. 
Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys.
Præbehandling med gentagne doser af rifampicin 600 mg efterfulgt af enkeltdosis Imatinib 400 mg resulterede i fald i Cmax og AUC(0-∞) på mindst 54% og 74% af værdierne uden rifampicinbehandling. 
Pretreatment with multiple doses of rifampicin 600 mg followed by a single 400 mg dose ofimatinibresulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment.
Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. 
However, always take this medicine exactly as your doctor or pharmacist has told you.
Patienter, får behandling med Imatinib Accord og er bekymrede for deres fertilitet, bør konsultere deres læge. 
Patients on imatinib treatment who are concerned about their fertility should consult with their physician.
Imatinib var teratogent hos rotter ved administration under organgenese ved doser ≥100 mg/kg, ca. svarende til den maksimale kliniske dosis på 800 mg/dag, baseret på legemsoverfladeareal. 
Imatinib was teratogenic in rats when administered during organogenesis at doses ≥ 100 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
• voksne og børn med Ph+ CML i kronisk fase efter manglende effekt af alfainterferonbehandling, eller i accelereret fase eller blastkrise. 
• adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
In vitro hæmmer Imatinib O-glucuronidationen af paracetamol med en Ki-værdi på 58,5 mikromol/l. 
In vitro, imatinib inhibits paracetamol O-glucuronidation with Ki value of 58.5 micromol/l.
Kvinder i den fertile alder Kvinder i den fertile alder skal tilrådes at anvende sikker kontraception under behandlingen. 
Women of childbearing potential must be advised to use effective contraception during treatment.
• voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD) som er forbundet med platelet-derived growth factor receptor-omlejring (PDGFR-omlejring). 
• adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
I undersøgelsen med patienter med inoperabel og/eller metastaserende GIST, oplevede 7 (5%) af patienterne CTC grad 3-4: gastrointestinale blødninger (3 patienter), intra-tumorale blødninger (3 patienter) eller begge dele (1 patient). 
In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade 3/4 GI bleeds (3 patients), intra-tumoural bleeds (3 patients) or both (1 patient).
- Øvrige indholdsstoffer: mikrokrystallinsk cellulose, crospovidon, hypromellose 6 cps (E464), magnesiumstearat og vandfri kolloid silica.Tabletovertrækket består af hypromellose 6 cps (E464), talkum (E553b), polyethylenglycol, gul jernoxid (E172) og rød jernoxid (E172). 
- The other ingredients are microcrystalline cellulose, crospovidone, hypromellose 6 cps (E464), magnesium stearate and anhydrous colloidal silica.The tablet coating is made of hypromellose 6 cps (E464), talc (E553b), polyethylene glycol, iron oxide yellow (E172) and iron oxide red (E172).
Tabel 4 Kemoterapiregime anvendt i kombination med imatinib 
Table 4 Chemotherapy regimen used in combination with imatinib
Cytogenetisk respons Major respons n (%) [95 % CI] 
Major response n (%) [95% CI]
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med imatinib i alle undergrupper af den pædiatriske population med Philadelphiakromosom (bcr-abl translokation)-positiv kronisk myeloid leukæmi (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with imatinib in all subsets of the paediatric population in Philadelphia chromosome (bcr-abl translocation)-positive chronic myeloid leukaemia (see section 4.2 for information on paediatric use).
ANC = fuldstændigt antal neutrofilocytter aopstået efter mindst 1 måneds behandling 
ANC = absolute neutrophil count aoccurring after at least 1 month of treatment Special populations Hepatic insufficiency
Pædiatriske patienter: Ialt 26 pædiatriske patienter i alderen <18 år med enten CML i kronisk fase (n=11) eller CML i blastkrise eller Ph+ akut leukæmi (n=15) blev inkluderet i en fase I undersøgelse med dosis-eskalering. 
A total of 26 paediatric patients of age < 18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose-escalation phase I trial.
Imatinib Accord er en behandling til voksne og børn og unge mod: 
Imatinib Accord is a treatment for adults and children and adolescents for:
Hvis dosis tolereres, kan den øges ved manglede effekt (se pkt. 
If tolerated, the dose can be increased for lack of efficacy (see sections 4.4 and
I undersøgelsen med patienter med inoperabel og/eller metastaserende GIST rapporteredes anæmi grad 3 og 4 hos henholdsvis 5,4% og 0,7% af patienterne, hvilket kan hænge sammen med gastrointestinal eller intra-tumoral blødning, i hvert fald hos enkelte af patienterne. 
In the study in patients with unresectable and/or metastatic GIST, grade 3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intra-tumoural bleeding in at least some of these patients.
Der er udført tre store, internationale, åbne, ikke-kontrollerede fase II-undersøgelser med patienter med Philadelphia-kromosompositiv (Ph+) CML i fremskreden blastkrise eller accelereret fase, andre Ph+ - leukæmier eller med CML i kronisk fase men tidligere behandlet med alfa-interferonbehandling (IFN) uden effekt. 
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML in advanced blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy.
I et 2-års karcinogenicitetsstudie i rotter resulterede administration af imatinib på 15, 30 og 60 mg/kg/dag i en signifikant reduktion i levetiden ved 60 mg/kg/dag for hanner og for hunner ved ≥30 mg/kg/dag. 
In the 2-year rat carcinogenicity study administration of imatinib at 15, 30 and 60 mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60 mg/kg/day and females at ≥ 30 mg/kg/day.
Hvis du behandles for DSFP 
If you are being treated for DFSP
Genoptag behandling med Imatinib Accord 600 mg. 
Resume treatment with Imatinib Accord at 600 mg.
PVC/PVdC/aluminium-blister eller alu/alu-blister. 
PVC/PVdC/Alu or Alu/Alu blisters.
Den totale daglige dosis til børn og unge må ikke overstige 800 mg for CML-patienter og 600 mg for Ph+ALL-patienter. 
The total daily dose in children and adolescents must not exceed 800 mg with CML and 600 mg with Ph+ALL.
Udskilning af fri imatinib er sandsynligvis sammenlignelig for nedsat nyrefunktion og normal nyrefunktion, eftersom udskillelse via nyren kun udgør en mindre elimineringsvej for imatinib (se pkt. 
The free drug clearance of imatinib is probably similar between renal impairment and those with normal renal function, since renal excretion represents only a minor elimination pathway for imatinib (see sections 4.2 and 4.4).
I dette studie blev 14 patienter med HES/CEL behandlet med 100 mg1.000 mg imatinib daglig. 
In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily.
CLM i kronisk fase defineres ved, at alle følgende kriterier er opfyldt: blaster <15 % i blod og knoglemarv, perifere blodbasofiltal <20%, trombocyttal > 100 x 109 /l. 
Chronic phase CML is defined when all of the following criteria are met: blasts < 15% in blood and bone marrow, peripheral blood basophils < 20%, platelets > 100 x 109/l.
Doser på 260 og 340 mg/m2/dag til børn og unge gav samme optagelse som doser på henholdsvis 400 mg og 600 mg til voksne. 
Dosing in children and adolescents at 260 and 340 mg/m2/day achieved the same exposure, respectively, as doses of 400 mg and 600 mg in adult patients.
- Hypereosinofil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL). 
Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL).
• voksne og børn med nydiagnosticeret Philadelphiakromosom (bcr-abl) positiv (Ph+) kronisk myeloid leukæmi (CML), for hvilke knoglemarvstransplantation ikke anses for førstevalgsbehandling. 
• adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller 4. grads neutropeni (ANC <1,0 x 109/l) og trombocytopeni (trombocyttal <50 x 109/l) var 4-6 gange højere ved blastkrise og accelereret fase (59-64% og 44-63% for henholdsvis neutropeni og trombopeni) end ved sammenligning med nydiagnosticerede patienter med kronisk fase CML (16,7% neutropeni og 8,9% trombocytopeni). 
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0x109/1) and thrombocytopenias (platelet count < 50x109/1) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Imatinibs sikkerhed og virkning hos børn og unge under 18 år med MDS/MPD, DFSP og HES/CEL er ikke klarlagt i kliniske studier. 
The safety and efficacy of imatinib in children and adolescents with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Advarsler og forsigtighedsregler Kontakt lægen, før du tager Imatinib Accord: - hvis du har eller har haft lever-, nyre- eller hjerteproblemer. 
Talk to your doctor before taking Imatinib Accord: - if you have or have ever had a liver, kidney or heart problem.
• voksne patienter med refraktært hypereosiniphil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL) med FIP1L1-PDGFR-omlejring. 
• adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Supplerende kemoterapi omgange: høj-dosis kemoterapi med MTX 1 g/m2 i.v. 
Consolidation therapy Alternating chemotherapy course: high dose chemotherapy with MTX 1 g/m2 i.v.
Meget almindelig Kvalme, diarré, opkast, dyspepsi, abdominalsmerter6 Almindelig 
Very common Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain6 Common
(1 time), dag 2831, 35-38, 42-45; 6-MP 60 mg/m2 oral, dag 26-46 
(1 h), days 28-31, 35-38, 42-45; 6-MP 60 mg/ m2 oral, days 26-46
Imatinib Accord 400 mg filmovertrukne tabletter leveres i pakker, der indeholder 10, 30 eller 90 tabletter, men ikke alle pakningsstørrelser fås nødvendigvis i dit land. 
Imatinib Accord 400 mg film-coated tablets are supplied in packs containing 10, 30, or 90 tablets, but these may not all be available in your country.
• voksne og børn patienter med nydiagnosticeret Philadelphiakromosom positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. 
• Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
Der er begrænset erfaring hos børn og unge med MDS/MPD, DFSP og HES/CEL. 
There is very limited experience in children and adolescents with MDS/MPD, DFSP and HES/CEL.
(0,5 time), dag 7, 8, 14, 15; CP 500 mg/m2 i.v. 
(0.5 h), days 7, 8, 14, 15; CP 500 mg/ m2 i.v.
Den estimerede frekvens af patienter fri for progression til fremskreden fase eller blastkrise efter 84 måneder var signifikant højere i Imatinib-armen end i IFN-armen (92,5 % vs. 85,1 %, p<0,001. 
The estimated rate of patients free of progression to accelerated phase or blast crisis at 84 months was significantly higher in the Imatinib arm compared to the IFN arm (92.5% versus 85.1%, p<0.001).
Nedsat nyrefunktion: Patienter med nedsat nyrefunktion eller i dialyse bør gives den mindste anbefalede dosis på 400 mg dagligt som startdosis. 
Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400 mg daily as starting dose.
Der sås signifikant øgning i følsomhed for imatinib (gennemsnitlig Cmax og AUC for imatinib steg med henholdsvis 26% og 40%) hos raske frivillige ved samtidig administration af enkeltdosis ketoconazol (en CYP3A4-hæmmer). 
There was a significant increase in exposure to imatinib (the mean Cmaxand AUC of imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a single dose of ketoconazole (a CYP3A4 inhibitor).
Der anbefales en dosering på 340 mg/m2 daglig til børn og unge med CML i kronisk fase og i fremskredne faser (må ikke overskride en total dosering på 800 mg). 
The dose of 340 mg/m2 daily is recommended for children and adolescents with chronic phase CML and advanced phase CML (not to exceed the total dose of 800 mg).
Herpes zoster, herpes simplex, nasopharyngitis, pneumoni1, sinuitis, cellulitis, infektioner i øvre luftveje, influenza, urinvejsinfektion, gastroenteritis, sepsis 
Herpes zoster, herpes simplex, nasopharyngitis, pneumonia1, sinusitis,cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis
Hvis noget af det ovenstående gælder for dig, skal du fortælle din læge det, før du tager Imatinib Accord. 
If any of these apply to you, tell your doctor before taking Imatinib Accord.
(q 12 timer), dag 2-3, i 4 cyklus 
(q 12 h), days 2-3, for 4 cycles
Imatinib Accord anvendes til behandling af voksne med: 
Imatinib Accord is a treatment for adults for:
• Kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ubehag forbundet med abnorme resultater af laboratorieprøver (f.eks. højt indhold af kalium-, urinsyre og calcium i blodet og lavt indhold af fosfor i blodet). 
• Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (e.g. high potassium, uric acid and calcium levels and low phosphorous levels in the blood).
* Denne type bivirkninger er hovedsageligt blevet rapporteret efter markedsføring af Imatinib. 
Blood amylase increased * These types of reactions have been reported mainly from post-marketing experience with Imatinib.
Der er begrænset erfaring hos børn og unge og Phpositiv ALL og meget begrænset erfaring med børn og unge med MDS/MPD, DFSP og HEL/CEL. 
There is limited experience in children and adolescents with Ph-positive ALL and very limited experience in children and adolescents with MDS/MPD, DFSP and HES/CEL.